The data strengthen SUBLOCADE’s value proposition in a competitive OUD market—watch for increased payer and provider adoption. Monitor upcoming regulatory or payer decisions for potential access expansions.
Price Chart
Executive Summary
Indivior presented new real-world evidence at the ASAM Conference showing that its long-acting buprenorphine therapy SUBLOCADE is associated with lower rates of fatal and non-fatal opioid overdoses compared to other treatments or no treatment. The data also support remission—beyond abstinence—as a meaningful recovery endpoint, reinforcing SUBLOCADE's clinical value in opioid use disorder (OUD) treatment.
Key Facts
- SUBLOCADE accounted for the smallest proportion of non-fatal and fatal opioid overdose events among all MOUD treatments in a real-world Ontario study of over 45,000 patients.
- Higher MOUD coverage (>80% time on treatment) correlated with significantly lower overdose risk.
- Provisional ROUTE Study data show patients in remission (absence of DSM-5 symptoms except craving) had better quality of life, lower pain, and lower unemployment.
- Over 500,000 patients have been prescribed SUBLOCADE globally.
Financial Impact
Positive reinforcement of SUBLOCADE's clinical differentiation and real-world effectiveness; may support pricing, reimbursement, and market share stability.
Risk Factors
- Study limitations include reliance on administrative data with potential misclassification.
- No direct financial or revenue metrics were disclosed, limiting immediate earnings impact.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3280930 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | EFFECT | $34.47 $35.53 | ▲ +3.08% | ▲ +2.97% | $35.71 (+3.60%) |
Aug 28, 2026 4w ago | S-4 | $34.93 $34.32 | ▼ −1.75% | ▼ −1.60% | $35.71 (+2.23%) |
Aug 3, 2026 8w ago | 425 / 8-K | $37.37 $38.47 | ▲ +2.94% | ▲ +0.92% | $35.71 (−4.44%) |
Aug 3, 2026 8w ago | 425 | $37.37 $38.47 | ▲ +2.94% | ▲ +0.92% | $35.71 (−4.44%) |
Aug 3, 2026 8w ago | 8-K | $37.37 $38.47 | ▲ +2.94% | ▲ +0.92% | $35.71 (−4.44%) |
Aug 3, 2026 8w ago | 425 / 8-K | $37.37 $38.47 | ▲ +2.94% | ▲ +0.92% | $35.71 (−4.44%) |
Jul 23, 2026 10w ago | Press Release | $40.51 $40.22 | ▼ −0.72% | ▼ −1.19% | $35.71 (−11.85%) |
Jun 12, 2026 16w ago | Insider Cluster | $38.40 $38.32 | ▼ −0.21% | ▲ +1.17% | $35.71 (−7.01%) |
May 15, 2026 20w ago | 8-K | $36.54 $37.81 | ▲ +3.48% | ▲ +1.86% | $35.71 (−2.27%) |
May 4, 2026 21w ago | 8-K | $38.98 $38.84 | ▼ −0.36% | ▼ −3.30% | $35.71 (−8.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access